Next Generation Natural Killer Cells for Cancer Immunotherapy

Area of Science:

• Immunology and Cancer Therapy

Background:

• Immunotherapy, including Chimeric Antigen Receptor (CAR)-T cell therapy, is a mainstream cancer treatment but faces challenges like high cost, complex manufacturing, and severe adverse events (e.g., cytokine release syndrome).
• Natural Killer (NK) cells possess inherent anti-tumor activity and offer potential advantages over CAR-T cells, including the possibility of allogeneic 'off-the-shelf' products.

Purpose of the Study:

• To review recent advances in the engineering of NK cells for cancer immunotherapy.
• To discuss the potential of engineered NK cells as a safer and more accessible alternative to current immunotherapies.

Main Methods:

• Review of current literature on NK cell sourcing and engineering technologies.
• Analysis of clinical trials involving engineered NK cells.
• Discussion of receptor engineering, immune evasion strategies, and next-generation 'armored' NK cell concepts.

Main Results:

• Engineering enhances NK cell ability to target tumors, improve persistence, and resist the tumor microenvironment.
• Allogeneic NK cell products offer potential for reduced cost and increased patient accessibility.
• Ongoing research focuses on improving NK cell functionality, tumor infiltration, and overcoming immune evasion.

Conclusions:

• Engineered NK cells represent a rapidly advancing field with significant potential to overcome limitations of current cancer immunotherapies.
• Future NK cell therapies aim for enhanced anti-tumor efficacy, improved safety, and broader clinical application.